{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:11:20Z","timestamp":1773195080082,"version":"3.50.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor lysis syndrome (TLS) is a major metabolic emergency in pediatric oncology and a leading cause of acute kidney injury (AKI) in children with hematological malignancies. Early identification of children at risk for severe AKI remains challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 50 children with laboratory or clinical TLS diagnosed according to the Howard\u2013Pui classification. Serial biochemical parameters were analyzed over a 10-day period. AKI severity was classified using the pediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria based on changes in estimated glomerular filtration rate (eGFR). Clinical characteristics, biochemical trends (especially phosphate and uric acid), and outcomes were compared between children with mild (pRIFLE 0 [no AKI]\/R\/I) and severe (pRIFLE-F) AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-seven patients had acute lymphoblastic leukemia (ALL), and 23 had lymphoma, mainly Burkitt\u2019s lymphoma. Clinical TLS accounted for 86% of cases, and 60% of children developed severe AKI. Severe AKI was significantly associated with spontaneous TLS onset, prolonged TLS duration, increased need for kidney therapy, intensive care admission, and higher mortality. Static demographic characteristics, malignancy type, tumor burden, and radiological findings did not differ between AKI severity groups. While hyperphosphatemia and hyperuricemia were common, dynamic phosphate changes showed the strongest association with AKI severity. The daily rise in serum phosphate before AKI onset demonstrated good discriminatory performance for predicting severe AKI (AUC 0.839), outperforming changes in uric acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In pediatric TLS, AKI severity is the main determinant of clinical outcome. Dynamic phosphate kinetics (Delta phosphorus), rather than static biochemical thresholds, represent a robust early biomarker for identifying children at risk of severe AKI and may improve risk stratification, particularly in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1778776","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:30:53Z","timestamp":1773120653000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor lysis syndrome in children with hematological malignancies: a nephrology perspective in resource-limited settings"],"prefix":"10.3389","volume":"16","author":[{"given":"Samar Atef","family":"Elshafey","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Unit, Department of Pediatrics, Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamiaa","family":"Essa","sequence":"additional","affiliation":[{"name":"Borg El-Arab Pediatric Oncology Center, Department of Pediatrics, Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Youssef","family":"Zeid","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology Unit, Department of Pediatrics, Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[{"name":"Department of Child Health, College of Medicine and Health Sciences, Sultan Qaboos University","place":["Muscat, Oman"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"El Chazli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology Unit, Department of Pediatrics, Faculty of Medicine, Alexandria University","place":["Alexandria, Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","article-title":"Tumor lysis syndrome","volume":"28","author":"Barbar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021070997","article-title":"Tumor lysis syndrome and AKI: beyond crystal mechanisms","volume":"33","author":"Arnaud","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0119497","DOI":"10.1371\/journal.pone.0119497","article-title":"Uric acid and the prediction models of tumor lysis syndrome in AML","volume":"10","author":"Ejaz","year":"2015","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2017.01.008","article-title":"Tumor lysis syndrome: A unique solute disturbance","volume":"52","author":"Strauss","year":"2017","journal-title":"Nurs Clin North Am"},{"key":"B7","article-title":"Tumour Lysis Syndrome in children with haematological cancers: Experience at a tertiary care hospital in Karachi","volume":"68","author":"Saeed","year":"2018","journal-title":"J Pak Med Assoc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0278-RS","article-title":"Tumor lysis syndrome","volume":"143","author":"Williams","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.12669\/pjms.35.4.715","article-title":"Tumor lysis syndrome in pediatric acute lymphoblastic leukemia at tertiary care center","volume":"35","author":"Naeem","year":"2019","journal-title":"Pak J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e27401","DOI":"10.1002\/pbc.27401","article-title":"Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia\/lymphoma: Analysis from a resource-limited setting","volume":"65","author":"Gopakumar","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01263-7","article-title":"Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome","volume":"35","author":"Lemerle","year":"2022","journal-title":"J Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-023-05923-z","article-title":"Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome","volume":"38","author":"Bir\u00f3","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00122-5","article-title":"Estimated incidence, prevalence, mortality, and registration of childhood cancer (ages 0\u201314 years) in the WHO Eastern Mediterranean region: an analysis of GLOBOCAN 2020 data","volume":"6","author":"Fadhil","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002231","article-title":"Modified RIFLE criteria in critically ill children with acute kidney injury","volume":"71","author":"Akcan-Arikan","year":"2007","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13613-019-0580-1","article-title":"Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury","volume":"9","author":"Ehrmann","year":"2019","journal-title":"Ann Intensive Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with Malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.ajkd.2008.11.017","article-title":"Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary","volume":"53","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12878-018-0117-0","article-title":"Evaluation and characterization of tumor lysis syndrome before and after chemotherapy among pediatric oncology patients in Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia","volume":"18","author":"Micho","year":"2018","journal-title":"BMC Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/1658-5127.123304","article-title":"Tumor lysis syndrome in children with acute leukemia: Incidence and outcome","volume":"4","author":"Al Bagshi","year":"2013","journal-title":"J Appl Hematol"},{"key":"B22","first-page":"84","article-title":"Tumour lysis syndrome in haematological Malignancies","volume":"11","author":"Ansari","year":"2012","journal-title":"JLUMHS"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin\u2019s lymphoma in four European countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3816\/CLM.2008.n.003","article-title":"A comparison of inpatient length of stay and costs among patients with hematologic Malignancies (excluding hodgkin disease) associated with and without acute renal failure","volume":"8","author":"Candrilli","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/j.ackd.2013.07.001","article-title":"Tumor lysis syndrome: new challenges and recent advances","volume":"21","author":"Wilson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70092","article-title":"British Society for Haematology updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children with haematological Malignancies: A focus on patient safety","volume":"207","author":"Chan","year":"2025","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/pbc.24501","article-title":"SIOP PODC: recommendations for supportive care of children with cancer in a low-income setting","volume":"60","author":"Israels","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70194-3","article-title":"Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study","volume":"9","author":"Ribeiro","year":"2008","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102603","DOI":"10.1016\/j.ctrv.2023.102603","article-title":"Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel","volume":"120","author":"Perissinotti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.115","article-title":"Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin\u2019s lymphoma: results of the GRAAL1 (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Trial on Rasburicase Activity in Adult Lymphoma) study","volume":"21","author":"Coiffier","year":"2003","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"106298","DOI":"10.1016\/j.leukres.2020.106298","article-title":"Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia","volume":"89","author":"Martens","year":"2020","journal-title":"Leuk Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687152","article-title":"Rational use of rasburicase for the treatment and management of tumor lysis syndrome","volume":"24","author":"Shaikh","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e27236","DOI":"10.1002\/pbc.27236","article-title":"Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population","volume":"65","author":"Savva","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic Malignancies at intermediate to high TLS risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12028","article-title":"Febuxostat as a prophylaxis for tumor lysis syndrome in children with hematological Malignancies","volume":"37","author":"Kishimoto","year":"2017","journal-title":"Anticancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12839","article-title":"Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06413-6","article-title":"Allopurinol use leading to xanthine nephrolithiasis in pediatric tumor lysis syndrome: a case series","volume":"39","author":"Goswami","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9332-22","article-title":"Urine xanthine crystals in hematologic Malignancies with tumor lysis syndrome","volume":"61","author":"Ito","year":"2022","journal-title":"Intern Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0287-z","article-title":"Acute renal failure from xanthine nephropathy during management of acute leukemia","volume":"22","author":"LaRosa","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1234677","article-title":"Benefit of continuous kidney replacement therapy for managing tumor lysis syndrome in children with hematologic Malignancies","volume":"13","author":"Anderson","year":"2023","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2007.04.016","article-title":"Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients","volume":"19","author":"Miltiadous","year":"2008","journal-title":"Eur J Intern Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e38815","DOI":"10.7759\/cureus.38815","article-title":"Tumor genesis syndrome presenting as severe hypophosphatemia in a patient with T-cell acute lymphoblastic leukemia","volume":"15","author":"Dukmak","year":"2023","journal-title":"Cureus"},{"key":"B48","article-title":"Tumor genesis syndrome. Hypophosphatemia accompanying Burkitt\u2019s lymphoma cell leukemia","volume":"12","author":"Wollner","year":"1986","journal-title":"Miner Electrolyte Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4103\/2589-9309.305900","article-title":"Safety and efficacy of renal replacement therapy for acute kidney injury in tumor lysis syndrome","volume":"3","author":"Ahmed","year":"2020","journal-title":"Asian J Pediatr Nephrol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6174.1320-a","article-title":"Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma","volume":"1","author":"Kanfer","year":"1979","journal-title":"Br Med J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12415","article-title":"Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\u00e9animation Respiratoire et Onco-H\u00e9matologique","volume":"162","author":"Darmon","year":"2013","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13613-022-00990-1","article-title":"Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy","volume":"12","author":"Abdel-Nabey","year":"2022","journal-title":"Ann Intensive Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1159\/000509934","article-title":"Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress","volume":"45","author":"Matuszkiewicz-Rowinska","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13584","article-title":"Changing the terminology from kidney replacement therapy to kidney support therapy","volume":"25","author":"Raina","year":"2021","journal-title":"Ther Apher Dial"},{"key":"B56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/0886022X.2019.1705337","article-title":"Timing of initiation of renal replacement therapy in acute kidney injury: an updated meta-analysis of randomized controlled trials","volume":"42","author":"Zhang","year":"2020","journal-title":"Ren Fail"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2009.10.056","article-title":"Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management","volume":"55","author":"Abu-Alfa","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9684909","DOI":"10.1155\/2017\/9684909","article-title":"Tumor lysis syndrome in patients with hematological Malignancies","volume":"2017","author":"Belay","year":"2017","journal-title":"J Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12806","article-title":"Impact of dialysis requirement on outcomes in tumor lysis syndrome","volume":"22","author":"Garimella","year":"2017","journal-title":"Nephrol (Carlton)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:30:56Z","timestamp":1773120656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":59,"alternative-id":["10.3389\/fonc.2026.1778776"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1778776","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1778776"}}